Drugs / tripterygium wilfordii
tripterygium wilfordii
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00889694 | Oct 2008 → Jul 2009 | ankylosing spondylitis | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT03589833 | May 2019 → Mar 2022 | rheumatoid arthritis | Peking Union Medical College Hospital | Completed | Met primary |
| Phase not applicable4 trials | ||||||
| — | NCT01161459 | Jun 2010 → Apr 2012 | idiopathic membranous glomerulonephritis | Zhi-Hong Liu, M.D. | Completed | No outcome recorded |
| — | NCT00881309 | Mar 2009 → Apr 2011 | lupus nephritis | Nanjing University School of Medicine | Completed | No outcome recorded |
| — | NCT00801463 | Jan 2009 → Jan 2011 | focal segmental glomerulosclerosis, proteinuria | Nanjing University School of Medicine | Completed | No outcome recorded |
| — | NCT00801268 | Nov 2008 → Nov 2013 | autosomal dominant polycystic kidney disease | Zhi-Hong Liu, M.D. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tripterygium wilfordii | “YISAIPU is a recombinant human tumor necrosis factor receptor fusion protein, and tripterygium wilfordii is a chloroform/methanol extract of Tripterygium wilfordii Hook F.” NCT03589833 ↗ |
| Known as | T2w | “tripterygium wilfordii (T2w)” NCT03589833 ↗ |
| Known as | Tripterygium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00889694 ↗ |
| Known as | Tripterygium Capsule | “Clinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis” NCT00889694 ↗ |
| Known as | TwHF | “Tripterygium wilfordii Hook F (TwHF)” PMID 37657525 ↗ Aug 2023 |
| Modality | Traditional medicine (herbal / TCM) | “Tripterygium (TW) is a Chinese traditional patent drugs in treating chronic glomerulonephritis.” NCT00881309 ↗ |
| Route | Oral | “Pre 30mg/d +TW 120 mg/d, po for 12 weeks” NCT00801463 ↗ |